Inhibition of human neutrophil elastase (HNE), (EC 3.4.21.37), as an approa
ch to the treatment of inflammatory diseases in the chronic obstructive pul
monary disease (COPD) continuum, such as emphysema and chronic bronchitis,
is still an area of intense research within the pharmaceutical industry. Th
is review summarises some recent developments in the design and evaluation
of HNE inhibitors as therapeutic agents since the subject was last reviewed
in this publication in 1997.